clinical trial · NCT07753824
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
M.D. Anderson Cancer Center·phase2·not yet recruiting·n = 30
Phase IIIvonescimabIntraperitonealPaclitaxelHigh Grade MetastaticAppendiceal AdenocarcinomaIvonescimabIP PTX
brief summary
To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).
started
Jan 16, 2027
primary completion
Nov 28, 2031
completion
Nov 28, 2032
last updated
Aug 10, 2026
detailed description
Primary Objectives To evaluate the safety and efficacy as measured by the disease control rate (DCR) of Ivonescimab combined with IP PTX in patients with unresectable metastatic high-grade AA
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol